Horizon Pharma Announces Patent Litigation Settlement With Par Pharma

(RTTNews) - Horizon Pharma, Inc. (HZNP) Thursday said it entered into settlement and license agreements with Par Pharmaceutical Companies, Inc and its unit, Par Pharmaceutical, Inc., to resolve a patent litigation involving DUEXIS (ibuprofen and famotidine) tablets.

Pursuant to the license agreement, Horizon has granted non-exclusive right to market a generic ibuprofen and famotidine product in the U.S. under Par's Abbreviated New Drug Application, beginning January 1, 2023, or earlier under certain situations. The settlement agreement includes a stipulation by the parties requesting dismissal without prejudice of the lawsuit filed by Horizon in the U.S. District Court for the District of Delaware relating to the ANDA filed by Par with the FDA for a generic version of DUEXIS (ibuprofen and famotidine) tablets.